

Title:

Circulating inflammatory cell profiling and periodontitis: a systematic review and meta-analysis

1

2 Authors:

3 Rizky A. Irwandi¹, Sandra O. Kuswandani^{1,2}, Simon Harden³, Debora Marletta⁴,

4 Francesco D'Aiuto¹

5

6 Institutional affiliations:

7 1. Periodontology Unit, Eastman Dental Institute, University College London,
8 London, United Kingdom

9 2. Department of Periodontology, Faculty of Dentistry, Universitas Indonesia,
10 Jakarta, Indonesia

11 3. Department of Statistical Science, University College London, London, United
12 Kingdom

13 4. Cruciform Hub, University College London, London, United Kingdom

14

15 Corresponding author:

16 Francesco D'Aiuto

17 Periodontology Unit

18 UCL Eastman Dental Institute

19 21 University Street

20 London WC1E 6DE

21 United Kingdom

22 f.daiuto@ucl.ac.uk

23 **Abstract**

24 Inflammation is a key driver of common non-communicable diseases. Among
25 common triggers of inflammation, chronic gingival inflammation (periodontitis)
26 triggers a consistent humoral host inflammatory response, but little is known on its
27 impact on circulating inflammatory cell profiles. We aimed to systematically appraise
28 all the evidence linking periodontitis and its treatment to circulating inflammatory cell
29 profiles. From six databases, 157 studies were eligible for qualitative synthesis and
30 29 studies for meta-analysis. Our meta-analysis showed that participants with
31 periodontitis exhibited a significant mean increase in circulating CD4⁺,
32 CD4⁺CD45RO⁺, IFN γ -expressing CD4⁺ and CD8⁺ T cells, CD19⁺CD27⁺ and CD5⁺ B
33 cells, CD14⁺CD16⁺ monocytes, and CD16⁺ neutrophils but decrease in CD8⁺ T and
34 CD14⁺⁺CD16⁻ monocytes. Our qualitative synthesis revealed that peripheral blood
35 neutrophils of patients with periodontitis consistently showed elevated production of
36 reactive oxygen species (ROS) when compared to those of healthy controls. Some
37 evidence suggested that the treatment of periodontitis reversed the exaggerated
38 ROS production, but limited and inconclusive data was found on several circulating
39 inflammatory cell profiling. We conclude that periodontitis and its treatment are
40 associated with minor but consistent alterations in circulating inflammatory cell
41 profiles. These changes could represent key mechanisms explaining the association
42 of periodontitis with other co-morbidities such as cardiovascular disease, diabetes,
43 and rheumatoid arthritis.

44 **Introduction**

45 Inflammation is a body response to infection or injury aimed at promoting tissue and
46 overall homeostasis. Evidence accumulated in the past three decades confirmed that
47 inflammation not only forces a transient impair in tissue function, but in turn could
48 contribute to the pathogenesis of other systemic diseases and altered homeostasis.¹
49 Inflammatory cells, such as neutrophils, monocytes, macrophages, and dendritic
50 cells initiate inflammation as part of an innate response.² The host mounts an
51 adaptive inflammatory response, which is mediated by dendritic cells and NK cells to
52 promote T and B lymphocytes functions. The expected outcome of these changes is
53 to achieve a complete resolution of the inflammatory response and alleviate the
54 damage in tissues where the response takes place.³ Inflammation however plays a
55 key role in the onset and progression of several chronic non-communicable diseases
56 such as Cardiovascular Disease (CVD), Type 2 Diabetes (T2D), and Rheumatoid
57 Arthritis (RA).⁴ Sources of inflammation in non-communicable diseases are still not
58 completely understood.

59 Periodontitis is a common chronic inflammatory disease caused by a specific oral
60 dysbiosis and characterized by a progressive loss of soft and hard tissues keeping
61 the teeth.⁵ The disease onset and progression could span over decades and when
62 left untreated it leads inevitably not only to tooth loss but also to masticatory
63 impairment and negative influences on the patient's quality of life.^{5, 6} Periodontitis is
64 a major public health concern as it affects over the half of world's population and
65 increases costs of oral healthcare.^{7, 8}

66 There is convincing evidence to suggest that periodontitis triggers a systemic
67 inflammatory response, and this could explain its association with an increased
68 incidence of systemic health outcomes including cardiovascular events, T2D

69 complications, and onset and progression of RA.⁹⁻¹¹ One of the plausible
70 mechanisms that could explain these relationships is a change in key circulating
71 inflammatory cell profiles (both innate and adaptive immune systems).¹² No
72 collective evaluation of the whole available evidence, however, has been attempted
73 to date. Our aim was to perform a critical and systematic appraisal of the existing
74 evidence linking periodontitis and its treatment to circulating inflammatory cell
75 profiles including cell populations and their functions. The inflammatory cells profiled
76 were neutrophils, monocytes, and lymphocytes, whereas the cell functions evaluated
77 were inflammatory mediator releases, cellular functional activities and gene
78 expression or transcripts.

79

80 **Material and Methods**

81 The review process followed the Preferred Reporting Items for Systematic Reviews
82 and Meta-Analyses (PRISMA) 2020 guidelines.¹³ This study was registered with
83 PROSPERO (Registration Number CRD42020199995), an international prospective
84 register of systematic reviews (<https://www.crd.york.ac.uk/prospero/>).

85

86 **Eligibility Criteria**

87 Adults aged no less than 18 years old suffering from all forms of periodontitis and
88 undergoing any type of treatment of periodontitis (including whole mouth subgingival
89 scaling, surgical periodontal therapy, supra-gingival scaling and polishing, the
90 adjunctive use of locally delivered antimicrobial therapy, and/or systemic antibiotic
91 therapy) were the main inclusion criteria. With regards to study design, case control
92 studies, nonrandomized, and randomized controlled trials reporting the impact of

93 periodontitis and its treatment on circulating inflammatory cell populations and
94 functions were included.

95 Case reports and series, reviews, animal studies and studies including participants
96 under 18 years old, pregnant, or suffering from other systemic diseases were
97 excluded.

98 The inflammatory cells that were profiled were neutrophils, monocytes/macrophages,
99 lymphocytes which are T, B, and NK cells. The circulating inflammatory cell
100 populations were the proportion of the cells indicated by cell surface and/or
101 intracellular markers expressed by peripheral blood mononuclear cells (PBMCs)
102 using flow cytometry. Meanwhile, the function of the cells was the activity of the
103 peripheral blood-derived cells including the investigation on their intracellular
104 cytokine expressions, cytokine release, cellular functional activities, and gene
105 expression or transcripts.

106

107 **Search Strategy**

108 Six different electronic databases including the Cochrane CENTRAL, MEDLINE,
109 Embase, Web of science, Scopus and CINAHL up to March 2021 with no year
110 restriction but limited to English language were accessed using medical subject
111 headings and free text terms **(Supplementary Appendix)**. Further, manual
112 searches from original manuscripts references list and review articles were
113 conducted.

114

115 **Study Selection**

116 Two reviewers (RAI and SOK) independently searched titles and abstracts (when
117 available) and any disagreement was resolved by discussion or moved to full text

118 screening. Full reports were retrieved and examined independently in duplicates and
119 any disagreement was resolved by discussion and if necessary, a third reviewer (FD)
120 was consulted. If manuscripts were lacking all information necessary for the
121 appraisal, authors were contacted at least twice to retrieve missing data. Detailed
122 reasons for exclusion of studies were recorded in particular when randomized clinical
123 trials were identified (**Supplementary Table 1**).

124

125 **Data Extraction**

126 Data were grouped according to study design and reported in evidence tables
127 consisted of study characteristics data, population (age, sex, ethnicity, smoking
128 habit, and systemic health), exposure (case definition for periodontitis), intervention
129 (periodontal treatment modalities), outcome (inflammatory cell populations and
130 functional analysis to determine cell functions), and publication results/conclusions.

131

132 **Quality Assessment**

133 Quality assessment and risk of bias in observational studies, randomized controlled
134 trials, and non-randomized studies of interventions were assessed by Newcastle-
135 Ottawa Scale (NOS)¹⁴, revised Cochrane tool (RoB 2)¹⁵, and ROBINS-I tool¹⁶,
136 respectively.

137

138 **Data Analysis**

139 Descriptive (summary of evidence retrieved) and quantitative (meta-analysis)
140 methods were used to appraise the included evidence. For meta-analysis, Weighted
141 Mean difference (WMD) and 95% confidence intervals (CI) of the percentage of cell
142 populations between cases (patients with periodontitis) and healthy controls were

143 calculated using random-effect models when at least two studies with data were
144 available whilst fixed effect models were used for the remaining studies.
145 Heterogeneity was assessed using The Cochran Q heterogeneity statistic and
146 quantified with the I^2 statistic. The overall effect was considered statistically
147 significant if $p < 0.05$. Publication bias was ascertained using Egger's test¹⁷ and
148 visually assessed using funnel plots. Sensitivity analyses were performed in the
149 subgroup of studies with medium-low of risk of bias to confirm/confute the results of
150 the meta-analysis. Statistical analyses were performed using R package metafor
151 (version 2.0).¹⁸

152

153 **Results**

154 **Study Characteristics**

155 The electronic and manual searches identified 10875 articles of potential relevance
156 after removal of duplicates (**Figure 1**). Following title-abstracts screening, 320
157 articles were eligible for a full-text assessment. A total of 157 articles were included,
158 consisting of 129 case-control studies, 3 randomized controlled trials (RCTs) and 25
159 non-RCT interventional studies (**Supplementary Table 2 and 3**). Almost perfect
160 agreement between the two reviewers was observed (Kappa score of 0.94)

161 The majority of studies identified (144 studies) included participants with periodontitis
162 and healthy controls, whereas a small minority recruited patients with periodontitis
163 and reported the effect of periodontal treatment (without control). After screening for
164 available data 29 studies were included in quantitative analysis (**Table 1**) whilst the
165 remaining (157 studies) in qualitative analyses including intervention studies on
166 inflammatory cell populations (11 studies) and cell functions (21 studies).

167 Risk of bias varied across observational studies (**Supplementary Table 4**) because
168 of differences in a) the selection and definition of controls, b) hospital rather than
169 community settings where controls were recruited and c) ambiguous definitions and
170 descriptions of history of periodontitis. Meanwhile, the risk of bias for non-
171 randomized trials were of low (six studies), moderate (four studies), and serious
172 (three studies) (**Supplementary Table 5**). One RCT study of low risk of bias and two
173 of some concerns mainly due to the randomization, blinding of participants, and
174 research personnel descriptions completed our assessments (**Supplementary**
175 **Table 6**).

176

177 **Periodontitis on Circulating Inflammatory Cell Populations**

178 Total proportion of 21 cell populations originating from 29 studies were identified and
179 eligible for meta-analyses (**Table 2**). A statistically significant overall effect was
180 observed in twelve cell populations: two cell populations analyses revealed reduced
181 cell number proportions whilst other ten comparison of cell populations exhibited
182 elevated cell number proportions in patients with periodontitis when compared to
183 healthy controls. Heterogeneity varied enormously between meta-analyses (ranging
184 from 0%-94.24%).

185 **Figure 2A** shows a significant increased proportion of peripheral CD4⁺ (WMD of 4%,
186 95% CI 1% to 7%, p = 0.0144), whilst **Figure 2B** shows a reduced proportion of
187 peripheral CD8⁺ cells (WMD of 2%, 95% CI 1% to 4%, p = 0.0075) in patients with
188 periodontitis compared to healthy controls were observed in ten studies (**Table 2**).
189 No evidence of publication bias was observed (**Supplementary Figure 1**). Three
190 studies reported that the proportion of non-classical monocytes, CD14⁺CD16⁺ (WMD
191 of 4%, 95% CI 2% to 5%, p < 0.0001) and CD5⁺ B cells (WMD of 6%, 95% CI 3% to

192 10%, $p = 0.0001$) were increased peripheral blood of patients with periodontitis
193 compared to healthy controls (**Table 2; Figure 3A-B**). Lastly, fewer studies
194 confirmed that the peripheral blood of patients with periodontitis on average
195 exhibited higher proportions of CD16⁺ neutrophils (**Table 2; Figure 4A**), memory B
196 (CD19⁺CD27⁺), CD5⁺CD19⁺, CD20⁺CD23⁺, CD20⁺CD69⁺, CD25⁺ cells (**Table 2;**
197 **Supplementary Figure 2 – 3**), and lower proportions of classical monocytes
198 (CD14⁺⁺CD16⁻) (**Table 2; Figure 4B**). These findings were confirmed in studies with
199 low-moderate risk of bias.

200

201 **Periodontitis on Circulating Inflammatory Cell Functions**

202 We identified 26 functional analyses on circulating inflammatory cells between
203 patients with periodontitis and healthy controls in 97 included studies (**Table 3**).
204 These analyses, which were at least reported in two studies, consisted of reactive
205 oxygen species (ROS) production, proliferation, chemotaxis, phagocytosis,
206 adhesion, diacylglycerol kinase (DAGK) activity, tartrate-resistant acid phosphatase
207 formation and elastase activity, actin polymerization, 4 different intracellular
208 cytokines, and 13 different soluble inflammatory mediators.

209 Most of the included studies (24 studies) reported on ROS production in neutrophils.
210 Of these, 14 studies indicated that peripheral neutrophils from patients with
211 periodontitis exhibited higher production of ROS when compared to healthy controls
212 (**Table 3A**). ROS production detected using either luminol-enhanced^{52-54, 57, 58, 60, 64} or
213 lucigenin-enhanced^{51, 62, 71} chemiluminescence were consistently elevated in
214 stimulated neutrophils derived from peripheral blood of periodontitis patients.
215 Stimulations used in these experiments was heterogeneous including fMLP, PMA,
216 periodontal pathogens, opsonized *S.aureus* and *E.coli*. Unstimulated PBMCs and

217 neutrophils in patients with periodontitis exhibited increased ROS production using
218 flow cytometry and lucigenin-enhanced chemiluminescence respectively.^{49, 62, 71}
219 Similarly, the majority of studies reported an increased level of TNF- α in cells (5 out
220 of 9 studies) (**Table 3B**), a higher proliferative response of peripheral blood
221 mononuclear cells (PBMCs) (7 out of 15 studies) (**Table 3C**) and neutrophil elastase
222 activity (2 out of 2 studies) (**Table 3D**) were observed in patients with periodontitis.
223 In comparison to healthy controls, a significant mean increase of intracellular IFN- γ
224 expression was observed in both CD4⁺ cells (WMD of 1%, 95% CI 0% to 2%, p =
225 0.0242) and CD8⁺ cells (WMD of 2%, 95% CI 1% to 4%, p = 0.002) from
226 periodontitis patients (**Table 4; Figure 5**), whereas the expression of intracellular IL-
227 4 and IL-17 in CD4⁺ cells as well as IL-12 in CD14⁺ cells were not significantly
228 different between groups (**Table 4, Supplementary Figure 4**). Levels of IL-2, IL-4,
229 IL-12p70, DAGK, chemotactic response, and phagocytic activity were, however,
230 lower in the peripheral blood-derived cells from patients with periodontitis when
231 compared to that from healthy controls (**Table 3E – 3J**). The majority of studies
232 confirmed no difference in IL-6, IL-10, IL-1 β , IFN- γ , IL-8, PGE2, TGF- β , MCP-1, IL-
233 13 levels, and adhesion of cells isolated from peripheral blood in patients versus
234 controls (**Table 3K – 3T**), whereas the remaining analyses were inconclusive (**Table**
235 **3U – 3V**).

236

237 **Periodontitis Treatment on Circulating Inflammatory Cell Populations**

238 After a comprehensive search, 12 interventional studies reporting the effect of
239 periodontal treatment on peripheral inflammatory cell populations were identified
240 (**Supplementary Table 7**). Three studies were RCTs, and eight studies were non-
241 RCT interventional studies (**Supplementary Table 3**). These studies referred to

242 various periodontal treatment modalities including follow-up of various lengths. In
243 summary after periodontal treatment, reduced proportion of 32 circulating
244 inflammatory cell populations and increased percentage of 11 circulating
245 inflammatory cell populations were reported (**Supplementary Table 8**).

246 Within the neutrophil subset, suppressive neutrophils (CD16^{dim}CD62L^{bright}) and
247 CD62L⁻ neutrophils were reported to decrease up to 6 and 12 months after the
248 treatment, respectively, while an elevated proportion of normal neutrophils
249 (CD16^{bright}CD62L^{bright}) was reported at 3- and 6-month intervals.¹²¹ Natural killer cells
250 (CD16⁺CD56⁺), B cells (CD19⁺), and CD25⁺ cells were all reduced after periodontal
251 surgical treatment.¹²² A declined percentage of monocytes (CD14⁺) expressing
252 CD36, CD80, TLR2 or TLR4 were also reported after non-surgical periodontal
253 treatments.¹²³ The periodontal treatment including scaling and root planning (SRP)
254 followed by a systemic antibiotic therapy decreased circulating myeloid dendritic
255 cells (CD11c⁺CCR6⁺) and Th17 cells (CD4⁺IL-17⁺Foxp3^{+/-}).¹²⁴ Interestingly,
256 periodontal treatment with SRP only was able to decrease both IL-17⁺ and IL-
257 17⁺IFN- γ ⁺ cells.¹²⁵

258 Following periodontal treatment, the proportion of CD3⁺ and CD3⁺CD25⁺ cells were
259 higher, while CD3⁺CD45RA⁺ was lower than that in baseline of patients with
260 periodontitis.^{122, 126} Intensive periodontal therapy reduced activated (CD8⁺CD38⁺),
261 immunosenescent (CD8⁺CD28^{hull}), and CD57⁺CD8⁺ T cells, while control periodontal
262 therapy did not.¹²⁷ Further, the percentage of CD8⁺ T cells and their effector memory
263 (CCR7⁻CD45RA⁻) were lower after periodontal treatment compared to baseline. The
264 naive cytotoxic T (Tc) cells (CD8⁺CCR7⁺CD45RA⁺) were higher following treatment
265 compared to baseline.⁴⁶ Periodontal treatment reduced HLADR⁻, CD44⁻, CD49d⁻,
266 CD62-expressing CD4⁺ T cells¹²³, and effector memory T helper (Th) cells

267 (CD4⁺CCR7⁻CD45RA⁻)⁴⁶, whereas CD4⁺, naive Th cells (CD4⁺CCR7⁺CD45RA⁺),
268 and CD4⁺CD45RA⁺ cells were increased after the treatment (46, 127).^{46, 128}
269 Supra- and sub-gingival tooth cleaning modified the proportion of both double
270 positive (CD4⁺CD8⁺) or negative (CD4⁻CD8⁻) cells. Effector memory
271 (CD4⁺CD8⁺CCR7⁻CD45RA⁻) and central memory (CD4⁺CD8⁺CCR7⁺CD45RA⁻)
272 double positive cells were reduced, but their naive (CD4⁺CD8⁺CCR7⁺CD45RA⁺) and
273 effector memory expressing CD45RA (CD4⁺CD8⁺CCR7⁻CD45RA⁺) cells were
274 elevated following the intervention. Likewise, a reduction in the percentage of
275 effector memory double negative (CD4⁻CD8⁻CCR7⁻CD45RA⁻) and an increase in the
276 proportion of naive double negative cells (CD4⁻CD8⁻CCR7⁺CD45RA⁺) were also
277 observed after the treatment.⁴⁶

278 The alteration on the proportion of antigen (Ag)-specific T cells after periodontal
279 treatment were reported in one study.¹²⁹ PBMCs were stimulated with
280 *Fusobacterium nucleatum* or *Treponema denticola* Ag, labelled as FadA and Td92,
281 respectively then the observation of Ag-specific CD4⁺ and regulatory T cells
282 (CD4⁺Foxp3⁺) were accomplished. Periodontal treatment increased the FadA- and
283 Td92-specific CD4⁺ cells, whereas only Td92-specific regulatory T cells were
284 reduced in response to the intervention.¹²⁹ The final single study investigated the
285 effect of the treatment on T cell receptor (TCR) V α /V β in CD3⁺, but only TCR V β 22
286 were decreased at 24 months post-intervention.¹²⁶

287

288 **Periodontitis Treatment on Circulating Inflammatory Cell Functions**

289 In 21 non-RCT interventional studies, we identified 34 functional analyses to assess
290 the peripheral inflammatory cell functions following periodontal treatment
291 (**Supplementary Table 9**). The included analyses were proliferation, phagocytosis,

292 chemotactic activity, migration inhibition, neutrophil extracellular trap (NET), speed,
293 velocity, resultant vector length, ROS production, PGE₂, transcriptomic analysis,
294 inflammasomes (ASC and NLRP), enzymes (ATPase and caspase-1), transcription
295 factors (GATA-3, RORC, and T-bet), toll-like receptors (TLR-2 and TLR-4),
296 chemokines (MCP-1, MDC, MIP-1 α , MIP-1 β , RANTES), and cytokines (IFN- γ , IL-10,
297 IL-12, IL-17, IL-1 β , IL-4, IL-6, IL-8, and TNF- α) (**Supplementary Table 10**).

298 Proliferative response of T lymphocytes measured by autologous mixed lymphocyte
299 reaction was increased after successful periodontal treatment (45, 82, 127).^{45, 128, 130}

300 The treatment also improved the phagocytic activity of both peripheral blood
301 neutrophils and monocytes.^{66, 131} Circulating neutrophils and monocytes
302 demonstrated increased chemotactic activity following the intervention.⁹⁶ Meanwhile,
303 a high variation of leukocyte migration inhibition was observed after the treatment,
304 depending on the group of samples, type of cell stimulation, and day of observation,
305 while the treatment consistently reduced leukocyte ATPase activity.¹³² Periodontal
306 treatment decreased NET production¹³³, neutrophil speed in response to chemo-
307 attractants (fMLP and CXCL8), neutrophil velocity, and accuracy after fMLP
308 stimulation, while neutrophil velocity and accuracy were normalized for CXCL8-
309 stimulated neutrophils.⁹⁷ The ROS production of peripheral blood neutrophil was
310 lower in post-treatment patients than that in pre-treatment.^{61, 62} In addition,
311 periodontal therapy did not affect PGE₂ production in whole blood cell culture.¹¹⁸

312 Transcriptomic analysis on peripheral monocytes revealed that the periodontal
313 therapy altered the expression of genes relevant to innate immunity, apoptosis, and
314 cell signaling.¹³⁴ Further, the alteration at transcriptional level in PBMCs involving
315 ASC, an inflammasome was decreased after therapy, whilst NLRP3 and its
316 downstream enzyme, Caspase-1 as well as TLR2 and TLR4 were not affected.^{135, 136}

317 In CD4+ cells, SRP modified the expression of genes encoding transcription factors,
318 RORC was reduced, while GATA-3 was increased after the treatment. No changes
319 in T-bet gene were reported in patients after treatment.¹²⁵
320 The production of chemokines and cytokines by peripheral blood-derived cells in
321 most of the collected evidence were not affected by periodontal treatment. The only
322 exception was for MCP-1, as either 4-week supplementation of liposomal bovine
323 lactoferrin or SRP and systemic antibiotic therapy reduced MCP-1 production by
324 PMBCs (when compared to pre-treatment values).^{124, 136} Periodontal treatment
325 reduced IFN- γ production of tetanus toxoid- or *Porphyromonas gingivalis*
326 (*P.gingivalis*) or Concanavalin A (ConA)-stimulated PBMCs or stimulated PBMCs, IL-
327 4 level of *P.gingivalis* or ConA-stimulated PBMCs, and lactoferrin supplementation
328 decreased IL-1 β , IL-6, and TNF- α in PBMCs.^{47, 129, 136} Lastly, monocyte IL-12p70
329 level increased in patients following SRP and systemic antibiotic administration when
330 compared to baseline values.^{107, 118}

331

332 **Discussion**

333 This is the systematic review confirming that periodontitis is not only a local
334 inflammatory disease, but it is accompanied by changes in proportion and function of
335 circulating inflammatory cells. Patients with periodontitis exhibited increased
336 numbers of circulating neutrophils (CD16+), T helper (CD4+), Tc1 (CD8⁺), memory
337 (CD19⁺CD27⁺), CD5⁺ B cells, and non-classical (CD14⁺CD16⁺) monocytes, whilst
338 reduced cytotoxic T cells (CD8⁺) and classical (CD14⁺⁺CD16⁻) monocytes when
339 compared to healthy controls. Patients with periodontitis also presented altered
340 functions of neutrophils and PBMCs (higher production and release of ROS and
341 TNF- α) when compared to controls. Reduced levels of IL-2, IL-4, IL-12p70, DAGK,

342 chemotactic responses, and phagocytic activity in peripheral inflammatory cells were
343 also found in patients suffering from periodontitis when compared to control.
344 Collectively a distinct systemic inflammatory cell-profiling is triggered by periodontitis,
345 and this could contribute to the aggravation or even initiation of other systemic
346 diseases.

347 Our quantitative analysis on innate inflammatory cells, including classical and non-
348 classical monocytes demonstrates that the host response profile present in patients
349 with periodontitis is similar to that was observed in other systemic inflammatory
350 diseases such as systemic lupus erythematosus (SLE), RA, and psoriasis. Common
351 features include lower proportion of classical monocytes and higher numbers of non-
352 classical monocytes.¹³⁷⁻¹³⁹ Meanwhile, for adaptive inflammatory cells, increased
353 CD5⁺ and memory B cells as reported in patients with SLE^{140, 141} as well as higher
354 IFN- γ -expressing Th CD4⁺¹⁴² and cytotoxic T CD8⁺ lymphocyte¹⁴³ as observed in
355 patients with psoriasis, have been reported in patients with periodontitis when
356 compared to healthy controls. Even hyperactive peripheral neutrophils features
357 reported in patients with periodontitis have been observed in patients with
358 inflammatory bowel diseases, including Crohn's disease and Ulcerative colitis.^{144, 145}

359

360 **Periodontitis to Altered Inflammatory Cell Profiles: Direct and Indirect** 361 **Mechanisms**

362 A number of direct and indirect mechanisms could be responsible for the systemic
363 alteration of circulating inflammatory cell proportions in patients with periodontitis.
364 There is sufficient preclinical evidence confirming that the dental plaque biofilm in
365 periodontitis stimulates antigen-presenting cells in the gingival tissues which in turn
366 trigger Th cells differentiation into Th1 cells.¹⁴⁶ This direct mechanism could explain

367 the increased proportion of CD4⁺ Th and IFN- γ -expressing CD4⁺ Th1 cells found in
368 the systemic circulation of patients with periodontitis. Further, increased cytotoxic
369 activity to eliminate damaged periodontal-derived cells could also explain the lower
370 proportions of peripheral CD8⁺ cytotoxic T cells but elevated IFN- γ -expressing CD8⁺
371 Tc1 cells. Meanwhile, antigen activation of periodontal bacteria on naive T cell may
372 contribute to an elevated proportion of CD4⁺CD45RO⁺ memory T cell population in
373 peripheral blood presented in our meta-analysis.

374 Alternatively, the increased local and systemic production of inflammatory
375 biomarkers could be an indirect mechanism altering myelopoiesis and granulopoiesis
376 of the bone marrow. IL-6 and IL-1 β influence hematopoietic stem and progenitor cell
377 (HPSC) differentiation towards the myeloid lineage, also known as trained
378 myelopoiesis.¹⁴⁷ This is supported by recent evidence suggesting that IL-6, induced
379 by *P.gingivalis* infection triggers osteoclast progenitor (OCP) expansion in the bone
380 marrow which ultimately activate osteoclastogenesis.¹⁴⁸ An alternative mechanism
381 could involve neural circuits, particularly those of the sympathetic nervous system
382 which innervates the bone marrow hematopoietic compartment, resulting in altered
383 hematopoiesis.¹⁴⁹ Systemic inflammation caused by periodontitis could also
384 stimulate trained granulopoiesis, resulting in hyper-responsive neutrophils increasing
385 their ROS and TNF- α productions.^{147, 150, 151} This is consistent with our qualitative
386 analysis of available evidence suggesting an elevated ROS and TNF α production in
387 neutrophils derived from peripheral blood of patients with periodontitis when
388 compared to healthy controls. In this context, TNF α is also a regulator of ROS
389 generation.¹⁵² Besides indirect stimulation by cytokines, HSPCs could directly
390 respond to commensal oral bacteria via their toll-like receptors (i.e. TLR4), resulting
391 in increased proliferation and differentiation towards myeloid lineage, and

392 preferential differentiation of lymphoid lineage into dendritic cells.¹⁵³ Our review
393 confirmed that alteration of peripheral lymphocytes could be a direct effect of skewed
394 myelopoiesis and/or due to the migration of activated lymphocytes previously primed
395 in inflamed periodontal tissues.¹⁵⁴

396

397 **Treatment of Periodontitis Modifies Circulating Inflammatory Cell Profiles**

398 This review also provides some initial evidence that periodontal treatment alters the
399 proportion and function of circulating inflammatory cells. Suppressive neutrophils,
400 TLR-expressing monocyte, immunosenescent cytotoxic T cells, naive, central, and
401 effector memory T cells were affected by periodontal treatment.^{46, 121, 123, 127} Further
402 improvement in phagocytic activity, chemotactic response, and ROS production of
403 peripheral blood-derived cells, including neutrophils and monocytes were noted.^{61, 62,}
404 ^{66, 96, 131} Collectively, this suggests a possible causal association between
405 periodontitis and proportion and function of circulating inflammatory cells. In turn, this
406 could also explain the association between periodontitis and other common chronic
407 co-morbidities, such as CVD and T2D. Further research, however, to address this
408 hypothesis is required.

409 Evidence suggested that the treatment of periodontitis could alleviate the symptoms
410 of patients with systemic inflammation such as, RA, SLE, and psoriasis. The current
411 systematic review and meta-analysis revealed evidence for a favorable effect of
412 periodontal treatment on RA activity.¹⁵⁵ Patients suffering from RA and concomitant
413 periodontitis had lower disease activity score with 28 joint counts (DAS28),
414 erythrocyte sedimentation rate (ESR), tender joint counts (TJC), swollen joint counts
415 (SJC), visual analogical scale (VAS), and the level of serum CRP following
416 periodontitis treatment compared to without the treatment.¹⁵⁶ Further in a prospective

417 study, SLE disease activity index (SLEDAI) of patients with SLE and chronic
418 gingivitis was reduced six months after the management of the gingival
419 inflammation.¹⁵⁷ Lastly evidence from a single RCT suggested that treatment of
420 periodontitis improved clinical outcomes in patients with concomitant psoriasis.
421 Indeed 8-weeks after management of periodontitis patients with psoriasis exhibited
422 reduced disease area and severity index (PASI) score when compared to patients
423 who had delayed periodontal therapy .¹⁵⁸

424

425

426 **Implication of Periodontitis-induced Circulating Inflammatory Cell Alteration to**
427 **Non-communicable Diseases**

428 Recent evidence confirms the role of inflammatory cells in a number of chronic
429 diseases such as CVD, T2D, and RA. This includes cells involved in either innate
430 immune response, such as monocyte subsets, or adaptive immune response which
431 are T and B lymphocyte subsets. The contribution of these cells is evident in the
432 onset and/or progression of the non-communicable diseases mentioned above.

433 T lymphocyte subsets play a prominent role in the pathogenesis of atherosclerosis,
434 and the modification of these cells are linked to hypertension and the increased risk
435 of cardiovascular events. Antigen presenting cells recognize oxidized LDL (OxLDL)
436 antigenic peptide and ApoB activate CD4⁺ T cells and their differentiation into Th1
437 cells. These cells (marked as IFN- γ -expressing CD4⁺) have shown to promote
438 atherogenesis.¹⁵⁹ An experimental mouse model confirmed a crucial role of CD4⁺ T
439 cell-priming with antigen presenting cells and traffic between circulation and vessel
440 wall during early stages of atherosclerosis.¹⁶⁰ CD4⁺ cell trafficking markers, CD4492,
441 CD49d, CD62L, and CD11a were all implicated in the onset of atheroma.^{161, 162}
442 Interestingly, periodontal treatment reduced the proportion of CD44-, CD49d- and
443 CD62-expressing CD4⁺ T cells and activated (CD8⁺CD38⁺), immunosenescent
444 (CD8⁺CD28^{null}), and CD8⁺CD57⁺ T cells.^{123, 127} Increased peripheral effector memory
445 T helper cells have been linked to faster subclinical atherosclerosis and
446 cardiovascular events.¹⁶³ In this review, we identified evidence suggesting that
447 periodontal treatment reduced these T cell subsets.⁴⁶ Further research should
448 address the hypothesis that T lymphocyte subsets could be influenced by
449 periodontal treatment and link them to vascular phenotypes including endothelial
450 dysfunction and hypertension.

451 Monocyte subsets are also involved in atherosclerosis. Classical monocytes are
452 short-lived cells that can differentiate into monocyte-derived macrophages and
453 monocyte-derived dendritic cells.^{164, 165} These cells are recruited to the site of
454 inflammation, recognize and phagocytose pathogens, secrete various inflammatory
455 cytokines, and recruit other immune cells for regulation of the inflammatory
456 response.^{166, 167} A reduced number of peripheral classical monocytes in periodontitis
457 could be an indicator of enhanced inflammation within the periodontal tissue. On the
458 other hand, non-classical monocytes are considered patrolling cells that exhibit a
459 distinct motility and crawling pattern along the vasculature, at the luminal side of
460 vascular endothelium. Besides that, these cells recognize and clear dying endothelial
461 cells to maintain vascular homeostasis.¹⁶⁸ Endothelial dysfunction which is partly
462 induced by vascular inflammation is evident in patients with periodontitis.¹⁶⁹ It is easy
463 to speculate that alterations in peripheral non-classical monocytes in periodontitis
464 could be responsible of the vascular dysfunction (**Figure 6**).

465 Th1 and Th17 are both pro-inflammatory T cell subsets that are increased in T2D
466 and they are also linked to impaired insulin signaling and glucose tolerance.^{170, 171} A
467 reduced proportion of Treg cells which are usually involved in controlling excessive
468 pro-inflammatory responses has been reported in patients with diabetes.^{172, 173}
469 Similarly, B cells play an important role in metabolic diseases and in experimental
470 models, B2 B cells promote pro inflammatory responses and insulin resistance¹⁷⁴,
471 whereas B1a¹⁷⁵ and B1b¹⁷⁶ B cells ameliorated insulin resistance and glucose
472 intolerance. The results of our review confirmed increased proportions of IFN- γ -
473 expressing CD4⁺ Th1, CD20⁺CD23⁺ B (B2), and CD5⁺ B (B1a) cells, indicating that
474 alteration of these subsets in periodontitis may contribute to diabetes complications

475 **(Figure 6)**. Further research investigating the role of Th1-Th17 subsets in patients
476 with periodontitis and the impact of its treatment to T2D is recommended.
477 Several inflammatory cells, including monocytes, T and B cells orchestrate the
478 pathogenesis of RA. Conflicting evidence exists on the role of peripheral classical
479 monocytes and non-classical monocytes in patients with RA.¹³⁸ Experimental animal
480 models suggested that non-classical monocytes recruited to synovial joint,
481 differentiate into inflammatory macrophages inducing arthritis in mice.¹⁷⁷ Further, a
482 reduced proportion of circulating Treg cells is associated with early signs of the
483 disease (172) as these cells are responsible for immunosuppression (163),
484 particularly suppressing the pro-inflammatory function of Th17 (173) and Th1
485 (174).^{169, 178-180} Lastly, memory B cells contribute to osteoclastogenesis via
486 expression of RANKL¹⁸¹, whereas the generation of IgM autoantibody by CD5⁺ B
487 cells^{182, 183} in RA forms immune complex and drives synovial inflammation.^{11, 184, 185}
488 Our meta-analyses confirmed an increased percentage of non-classical monocytes
489 (CD14⁺CD16⁺), circulating memory (CD19⁺CD27⁺) and CD5⁺ B cells in patients with
490 periodontitis suggesting these cell subsets could explain a two-way relationship
491 between periodontitis and RA **(Figure 6)**.

492

493 **Study Limitation**

494 Some limitations should be highlighted in this systematic review starting with high
495 level of heterogeneity observed in the published evidence (mainly due the case
496 definition of periodontitis). Despite our sensitivity analyses in studies with medium-
497 low Risk of Bias, we urge caution in interpreting the results of the review especially
498 when inferring a causal association between periodontitis and inflammatory cell
499 subpopulation and their functions.¹⁸⁶ A wide variety of cell-functions assays/analyses

500 reported in small and often uncontrolled studies, undermine the potential impact of
501 periodontitis on cell proportions and their function. Nevertheless, this was the first
502 collective attempt of comprehensively appraise the evidence linking periodontitis to
503 circulating cell proportions and functional differences.

504

505 **Conclusion**

506 In conclusion, periodontitis is associated with alterations in peripheral inflammatory
507 cell profiles, and this could mediate the association of the disease with other
508 common systemic co-morbidities such as CVD, T2D and RA. Further research
509 should focus on models of inflammation to unravel the exact mechanisms of these
510 association as well as to demonstrate a potential benefit in treating periodontitis over
511 systemic complications in patients with other common co-morbidities by large
512 randomized clinical trials.

513

514 **Data Availability Statement**

515 Data supporting the finding of the study are available in this article and its
516 supplementary file, or from the corresponding author upon request.

517

518 **Conflict of Interest Disclosure**

519 The authors declare that the research was conducted in the absence of any
520 commercial or financial relationships that could be construed as a potential conflict of
521 interest.

522

523

524 **Authorship**

525 Rizky Aditya Irwandi (RAI), Sandra Olivia Kuswandani (SOK), Simon Harden (SH),
526 Debora Marletta (DM), Francesco D’Aiuto (FD).

527 RAI was involved in the formulation of study design, literature search, data curation,
528 data interpretation and writing the original draft. DM was involved in the search
529 strategies. SOK was involved in literature search and data curation. SH performed
530 the statistical analysis. FD was involved in the formulation of study design, writing
531 the original draft, data interpretation, and supervision of the study. All authors
532 approved the final version of the manuscript.

533

534 **Acknowledgement**

535 This study was completed at UCL Biomedical Research Centre which receives
536 funding from the NIHR. RAI and SOK received funding from the Indonesia
537 Endowment Fund for Education S-1692/LPDP.4/2019 (LPDP – Indonesia
538 Scholarship).

539 **References**

- 540 1. Medzhitov R. Origin and physiological roles of inflammation. *Nature* 2008;454:428-
541 435.
- 542 2. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. *Nat Rev Cancer*
543 2004;4:11-22.
- 544 3. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune
545 system. *Science* 2010;327:291-295.
- 546 4. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease
547 across the life span. *Nat Med* 2019;25:1822-1832.
- 548 5. Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases. *Nat Rev Dis*
549 *Primers* 2017;3:1-14.
- 550 6. Graziani F, Music L, Bozic D, Tsakos G. Is periodontitis and its treatment capable of
551 changing the quality of life of a patient? *Br Dent J* 2019;227:621-625.
- 552 7. Kassebaum N, Bernabé E, Dahiya M, Bhandari B, Murray C, Marcenes W. Global
553 burden of severe periodontitis in 1990-2010: a systematic review and meta-regression.
554 *J Dent Res* 2014;93:1045-1053.
- 555 8. Baehni P, Tonetti M, Periodontology GotEWo. Conclusions and consensus statements
556 on periodontal health, policy and education in Europe: a call for action—consensus
557 view 1: Consensus report of the 1st European Workshop on Periodontal Education.
558 *Eur J Dent Educ* 2010;14:2-3.
- 559 9. Sanz M, Marco del Castillo A, Jepsen S, et al. Periodontitis and cardiovascular
560 diseases: Consensus report. *J Clin Periodontol* 2020;47:268-288.
- 561 10. Preshaw PM, Bissett SM. Periodontitis and diabetes. *Br Dent J* 2019;227:577-584.
- 562 11. Potempa J, Mydel P, Koziel J. The case for periodontitis in the pathogenesis of
563 rheumatoid arthritis. *Nat Rev Rheumatol* 2017;13:606-620.

- 564 12. Hajishengallis G, Chavakis T. Local and systemic mechanisms linking periodontal
565 disease and inflammatory comorbidities. *Nat Rev Immunol* 2021;1-15.
- 566 13. Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting
567 systematic reviews: development of the PRISMA 2020 statement. *J Clin Epidemiol*
568 2021;134:103-112.
- 569 14. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for
570 assessing the quality of nonrandomised studies in meta-analyses. In: Oxford, 2000.
- 571 15. Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in
572 randomised trials. *BMJ* 2019;366.
- 573 16. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias
574 in non-randomised studies of interventions. *BMJ* 2016;355.
- 575 17. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a
576 simple, graphical test. *BMJ* 1997;315:629-634.
- 577 18. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat*
578 *Softw* 2010;36:1-48.
- 579 19. Afar B, Engel D, Clark E. Activated lymphocyte subsets in adult periodontitis. *J*
580 *Periodontal Res* 1992;27:126-133.
- 581 20. Aoyagi T, Sugawara-Aoyagi M, Yamazaki K, Hara K. Interleukin 4 (IL-4) and IL-6-
582 producing memory T-cells in peripheral blood and gingival tissues in periodontitis
583 patients with high serum antibody titers to Porphyromonas gingivalis. *Oral Microbiol*
584 *Immunol* 1995;10:304-310.
- 585 21. Berglundh T, Liljenberg B, Tarkowski A, Lindhe J. Local and systemic TCR V gene
586 expression in advanced periodontal disease. *J Clin Periodontol* 1998;25:125-133.

- 587 22. Berglundh T, Liljenberg B, Tarkowski A, Lindhe J. The presence of local and
588 circulating autoreactive B cells in patients with advanced periodontitis. *J Clin*
589 *Periodontol* 2002;29:281-286.
- 590 23. Buduneli N, Bıçakçı N, Keskinog˘lu A. Flow-cytometric analysis of lymphocyte
591 subsets and mCD14 expression in patients with various periodontitis categories. *J*
592 *Clin Periodontol* 2001;28:419-424.
- 593 24. Cheng WC, van Asten SD, Burns LA, et al. Periodontitis-associated pathogens *P.*
594 *gingivalis* and *A. actinomycetemcomitans* activate human CD14+ monocytes leading
595 to enhanced Th17/IL-17 responses. *European journal of immunology* 2016;46:2211-
596 2221.
- 597 25. Cheng WC, Saleh F, Abuaisa Karim B, Hughes FJ, Taams LS. Comparative analysis
598 of immune cell subsets in peripheral blood from patients with periodontal disease and
599 healthy controls. *Clin Exp Immunol* 2018;194:380-390.
- 600 26. Demoersman J, Pochard P, Framery C, et al. B cell subset distribution is altered in
601 patients with severe periodontitis. *PloS One* 2018;13:e0192986.
- 602 27. Gemmell E, Seymour G. Phenotypic analysis of B-cells extracted from human
603 periodontal disease tissue. *Oral Microbiol Immunol* 1991;6:356-362.
- 604 28. Gemmell E, Seymour G. Cytokine profiles of cells extracted from humans with
605 periodontal diseases. *J Dent Res* 1998;77:16-26.
- 606 29. Gómez-Moreno G, Cutando-Soriano A, Arana C, et al. Melatonin expression in
607 periodontal disease. *J Periodontal Res* 2007;42:536-540.
- 608 30. Hetta HF, Mwafey IM, Batiha GE-S, et al. Cd19+ cd24hi cd38hi regulatory b cells
609 and memory b cells in periodontitis: Association with pro-inflammatory and anti-
610 inflammatory cytokines. *Vaccines* 2020;8:340.

- 611 31. Jagannathan R, Lavu V, Rao SR. Comparison of the proportion of non-classic
612 (CD14+ CD16+) monocytes/macrophages in peripheral blood and gingiva of healthy
613 individuals and patients with chronic periodontitis. *J Periodontol* 2014;85:852-858.
- 614 32. Kundu D, Bandyopadhyay P, Nair V, Chowdhury M, Mukherjee S, Nayek M.
615 Aggressive periodontitis: A clinico-hematological appraisal. *Journal of Indian society*
616 *of Periodontology* 2014;18:166.
- 617 33. Lima PMA, Souza PEA, Costa JE, Gomez RS, Gollob KJ, Dutra WO. Aggressive and
618 chronic periodontitis correlate with distinct cellular sources of key immunoregulatory
619 cytokines. *J Periodontol* 2011;82:86-95.
- 620 34. Mouynet P, Picot C, Nicolas P, et al. Ex vivo studies of polymorphonuclear
621 neutrophils from patients with early-onset periodontitis: (III). CR3 and LFA-1
622 expression by peripheral blood and gingival crevicular polymorphonuclear
623 neutrophils. *J Clin Periodontol* 1995;22:110-117.
- 624 35. Nagai A, Takahashi K, Sato N, et al. Abnormal proportion of $\gamma\delta$ T cells in peripheral
625 blood is frequently detected in patients with periodontal disease. *J Periodontol*
626 1993;64:963-967.
- 627 36. Nagasawa T, Nitta H, Watanabe H, Ishikawa I. Reduced CD8+ peripheral blood T
628 lymphocytes in rapidly progressive periodontitis. *Arch Oral Biol* 1995;40:605-608.
- 629 37. Nagasawa T, Kobayashi H, Aramaki M, Kiji M, Oda S, Izumi Y. Expression of
630 CD14, CD16 and CD45RA on monocytes from periodontitis patients. *J Periodontal*
631 *Res* 2004;39:72-78.
- 632 38. Nemoto E, Nakamura M, Shoji S, Horiuchi H. Circulating promyelocytes and low
633 levels of CD16 expression on polymorphonuclear leukocytes accompany early-onset
634 periodontitis. *Infect Immun* 1997;65:3906-3912.

- 635 39. Okada K, Fujimura T, Kikuchi T, et al. Effect of interleukin (IL)-35 on IL-17
636 expression and production by human CD4+ T cells. *PeerJ* 2017;5:e2999.
- 637 40. Schmidt J, Jentsch H, Stingu C-S, Sack U. General immune status and oral
638 microbiology in patients with different forms of periodontitis and healthy control
639 subjects. *PLoS One* 2014;9:e109187.
- 640 41. Seymour G, Taubman M, Eastcott J, Gemmell E, Smith D. CD29 expression on
641 CD4+ gingival lymphocytes supports migration of activated memory T lymphocytes
642 to diseased periodontal tissue. *Oral Microbiol Immunol* 1997;12:129-134.
- 643 42. Sugawara M, Yamashita K, Yoshie H, Hara K. Detection of, and anti-collagen
644 antibody produced by, CD5-positive B cells in inflamed gingival tissues. *J*
645 *Periodontal Res* 1992;27:489-498.
- 646 43. Tjoa ST, De Vries TJ, Schoenmaker T, Kelder A, Loos BG, Everts V. Formation of
647 osteoclast-like cells from peripheral blood of periodontitis patients occurs without
648 supplementation of macrophage colony-stimulating factor. *J Clin Periodontol*
649 2008;35:568-575.
- 650 44. Watanabe K, Blew B, Scherer M, et al. CD11b mRNA expression in neutrophils
651 isolated from peripheral blood and gingival crevicular fluid. *J Clin Periodontol*
652 1997;24:814-822.
- 653 45. Kimura S, Fujimoto N, Okada H. Impaired autologous mixed-lymphocyte reaction of
654 peripheral blood lymphocytes in adult periodontitis. *Infect Immun* 1991;59:4418-
655 4424.
- 656 46. Medara N, Lenzo JC, Walsh KA, et al. Peripheral memory T-cell profile is modified
657 in patients undergoing periodontal management. *J Clin Periodontol* 2021;48:249-262.

- 658 47. Medara N, Lenzo JC, Walsh KA, O'Brien-Simpson NM, Reynolds EC, Darby IB.
659 Peripheral T helper cell profiles during management of periodontitis. *J Clin*
660 *Periodontol* 2021;48:77-91.
- 661 48. Biasi D, Bambara LM, Carletto A, et al. Neutrophil migration, oxidative metabolism
662 and adhesion in early onset periodontitis. *J Clin Periodontol* 1999;26:563-568.
- 663 49. Bullon P, Cordero MD, Quiles JL, Morillo JM, del Carmen Ramirez-Tortosa M,
664 Battino M. Mitochondrial dysfunction promoted by Porphyromonas gingivalis
665 lipopolysaccharide as a possible link between cardiovascular disease and
666 periodontitis. *Free Radic Biol Med* 2011;50:1336-1343.
- 667 50. Carvalho RP, Mesquita JS, Bonomo A, Elsas PX, Colombo AP. Relationship of
668 neutrophil phagocytosis and oxidative burst with the subgingival microbiota of
669 generalized aggressive periodontitis. *Oral Microbiol Immunol* 2009;24:124-132.
- 670 51. Dias IH, Chapple IL, Milward M, et al. Sulforaphane restores cellular glutathione
671 levels and reduces chronic periodontitis neutrophil hyperactivity in vitro. *PLoS One*
672 2013;8:e66407.
- 673 52. Fredriksson M, Gustafsson A, Asman B, Bergström K. Hyper-reactive peripheral
674 neutrophils in adult periodontitis: generation of chemiluminescence and intracellular
675 hydrogen peroxide after in vitro priming and FcγR-stimulation. *J Clin*
676 *Periodontol* 1998;25:394-398.
- 677 53. Fredriksson MI, Figueredo CM, Gustafsson A, Bergström KG, Asman BE. Effect of
678 periodontitis and smoking on blood leukocytes and acute-phase proteins. *J*
679 *Periodontol* 1999;70:1355-1360.
- 680 54. Fredriksson MI, Gustafsson AK, Bergström KG, Asman BE. Constitutionally
681 hyperreactive neutrophils in periodontitis. *J Periodontol* 2003;74:219-224.

- 682 55. Fredriksson MI. Effect of priming in subpopulations of peripheral neutrophils from
683 patients with chronic periodontitis. *J Periodontol* 2012;83:1192-1199.
- 684 56. Gronert K, Kantarci A, Levy BD, et al. A molecular defect in intracellular lipid
685 signaling in human neutrophils in localized aggressive periodontal tissue damage. *J*
686 *Immunol* 2004;172:1856-1861.
- 687 57. Guentsch A, Puklo M, Preshaw PM, et al. Neutrophils in chronic and aggressive
688 periodontitis in interaction with *Porphyromonas gingivalis* and *Aggregatibacter*
689 *actinomycetemcomitans*. *J Periodontal Res* 2009;44:368-377.
- 690 58. Gustafsson A, Ito H, Asman B, Bergström K. Hyper-reactive mononuclear cells and
691 neutrophils in chronic periodontitis. *J Clin Periodontol* 2006;33:126-129.
- 692 59. Johnstone AM, Koh A, Goldberg MB, Glogauer M. A hyperactive neutrophil
693 phenotype in patients with refractory periodontitis. *J Periodontol* 2007;78:1788-1794.
- 694 60. Kim KY, Kim M-K, Choi YS, et al. A Hyperactive Neutrophil Phenotype in
695 Aggressive Periodontitis. *Int J Oral Biol* 2012;37:69-75.
- 696 61. Kimura S, Yonemura T, Kaya H. Increased oxidative product formation by peripheral
697 blood polymorphonuclear leukocytes in human periodontal diseases. *J Periodontal*
698 *Res* 1993;28:197-203.
- 699 62. Ling MR, Chapple IL, Matthews JB. Neutrophil superoxide release and plasma C-
700 reactive protein levels pre-and post-periodontal therapy. *J Clin Periodontol*
701 2016;43:652-658.
- 702 63. Loesche WJ, Robinson JP, Flynn M, Hudson JL, Duque RE. Reduced oxidative
703 function in gingival crevicular neutrophils in periodontal disease. *Infect Immun*
704 1988;56:156-160.

- 705 64. Matthews JB, Wright HJ, Roberts A, Cooper PR, Chapple IL. Hyperactivity and
706 reactivity of peripheral blood neutrophils in chronic periodontitis. *Clin Exp Immunol*
707 2007;147:255-264.
- 708 65. Mouynet P, Delamaire M, Legoff MC, Genetet B, Yardin M, Michel JF. Ex vivo
709 studies of polymorphonuclear neutrophils from patients with early-onset-periodontitis
710 (II). Chemiluminescence response analysis. *J Clin Periodontol* 1994;21:533-539.
- 711 66. Naiff PF, Carneiro V, Guimarães MdCM, et al. Mechanical Periodontal Therapy
712 Recovered the Phagocytic Function of Monocytes in Periodontitis. *Int J Dent*
713 2020;2020.
- 714 67. Nicu EA, Rijkschroeff P, Wartewig E, Nazmi K, Loos BG. Characterization of oral
715 polymorphonuclear neutrophils in periodontitis patients: a case-control study. *BMC*
716 *Oral Health* 2018;18:149.
- 717 68. Paknejad M, Rokn AR, Touhid Amoli H. An Investigation on Chemotaxis Activity,
718 Respiratory Explosion and the Phagocytosis of Peripheral Blood Neutrophils in
719 Patients Affected With EOP. *J Dent* 2004;1:49-55.
- 720 69. Takahashi K, Ohyama H, Kitanaka M, et al. Heterogeneity of host immunological risk
721 factors in patients with aggressive periodontitis. *J Periodontol* 2001;72:425-437.
- 722 70. Tufano MA, Ianniello R, Sanges MR, Rossano F. Neutrophil function in rapidly
723 progressive and adult periodontitis. *Eur J Epidemiol* 1992;8:67-73.
- 724 71. Žilinskas J, Žekonis J, Žekonis G, et al. Inhibition of peripheral blood neutrophil
725 oxidative burst in periodontitis patients with a homeopathic medication Traumeel S.
726 *Med Sci Monit* 2011;17:284-291.
- 727 72. Akramas L, Akramienė D, Sakalauskienė J, Kubilius R, Gleiznys A. Effect of
728 (1→3),(1→6)-β-glucan on in vitro production of cytokines by leukocytes of patients
729 with periodontitis. *Medicina* 2012;48:186-191.

- 730 73. Fokkema SJ, Loos BG, Slegte C, van der Velden U. A type 2 response in
731 lipopolysaccharide (LPS)-stimulated whole blood cell cultures from periodontitis
732 patients. *Clin Exp Immunol* 2002;127:374-378.
- 733 74. Gonçalves TO, Costa D, Brodskyn CI, Duarte PM, César Neto JB, Nogueira-Filho G.
734 Release of cytokines by stimulated peripheral blood mononuclear cells in chronic
735 periodontitis. *Arch Oral Biol* 2010;55:975-980.
- 736 75. Grenier D, Cazalis J, Gagnon G. Response of periodontitis and healthy patients in a
737 Porphyromonas gingivalis-stimulated whole-blood model. *J Investig Clin Dent*
738 2011;2:38-42.
- 739 76. Ling MR, Chapple IL, Matthews JB. Peripheral blood neutrophil cytokine hyper-
740 reactivity in chronic periodontitis. *Innate Immun* 2015;21:714-725.
- 741 77. Sakalauskiene J, Giedrimiene D, Kubilius R, et al. Cytokine production by leukocytes
742 in patients with periodontitis. *Cent Eur J Med* 2014;9:821-829.
- 743 78. Shapira L, Soskolne WA, Sela MN, Offenbacher S, Barak V. The secretion of PGE2,
744 IL-1 beta, IL-6, and TNF alpha by adherent mononuclear cells from early onset
745 periodontitis patients. *J Periodontol* 1994;65:139-146.
- 746 79. Aoyagi T, Yamazaki K, Kabasawa-Kato Y, et al. Elevated CTLA-4 expression on
747 CD4 T cells from periodontitis patients stimulated with Porphyromonas gingivalis
748 outer membrane antigen. *Clin Exp Immunol* 2000;119:280-286.
- 749 80. Boyatzis S, Seymour GJ. Effect of age and periodontal disease status in man on the
750 spontaneous proliferation of peripheral blood lymphocytes. *Arch Oral Biol*
751 1986;31:749-755.
- 752 81. Engel D, Monzingo S, Rabinovitch P, Clagett J, Stone R. Mitogen-induced
753 hyperproliferation response of peripheral blood mononuclear cells from patients with

- 754 severe generalized periodontitis: lack of correlation with proportions of T cells and T-
755 cell subsets. *Clin Immunol Immunopathol* 1984;30:374-386.
- 756 82. Evans RI, Mikulecky M, Seymour GJ. Effect of initial treatment of chronic
757 inflammatory periodontal disease in adults on spontaneous peripheral blood
758 lymphocyte proliferation. *J Clin Periodontol* 1989;16:271-277.
- 759 83. Figueira EA, de Rezende ML, Torres SA, et al. Inhibitory signals mediated by
760 programmed death-1 are involved with T-cell function in chronic periodontitis. *J*
761 *Periodontol* 2009;80:1833-1844.
- 762 84. Getka TP, Alexander DC, Parker WB, Miller GA. Immunomodulatory and
763 superantigen activities of bacteria associated with adult periodontitis. *J Periodontol*
764 1996;67:909-917.
- 765 85. Kopp W, Marggraf E. Blastogenetic responsiveness of peripheral blood lymphocytes
766 from patients with adult periodontitis, evaluated by a reverse hemolytic plaque assay.
767 *J Clin Periodontol* 1986;13:805-809.
- 768 86. Mangan DF, Laughon BE, Bower B, Lopatin DE. In vitro lymphocyte blastogenic
769 responses and titers of humoral antibodies from periodontitis patients to oral
770 spirochete isolates. *Infect Immun* 1982;37:445-451.
- 771 87. Page RC, Clagett JA, Engel LD, Wilde G, Sims T. Effects of prostaglandin on the
772 antigen- and mitogen-driven responses of peripheral blood lymphocytes from patients
773 with adult and juvenile periodontitis. *Clin Immunol Immunopathol* 1978;11:77-87.
- 774 88. Patters MR, Genco RJ, Reed MJ, Mashimo PA. Blastogenic response of human
775 lymphocytes to oral bacterial antigens: comparison of individuals with periodontal
776 disease to normal and edentulous subjects. *Infect Immun* 1976;14:1213-1220.

- 777 89. Patters MR, Chen P, McKenna J, Genco RJ. Lymphoproliferative responses to oral
778 bacteria in humans with varying severities of periodontal disease. *Infect Immun*
779 1980;28:777-784.
- 780 90. Petit MD, Wassenaar A, van der Velden U, van Eden W, Loos BG. Depressed
781 responsiveness of peripheral blood mononuclear cells to heat-shock proteins in
782 periodontitis patients. *J Dent Res* 1999;78:1393-1400.
- 783 91. Tew JG, Miller GA, Greene EJ, et al. Immunological studies of young adults with
784 severe periodontitis. II. Cellular factors. *J Periodontal Res* 1981;16:403-416.
- 785 92. Trindade SC, Olczak T, Gomes-Filho IS, et al. Porphyromonas gingivalis antigens
786 differently participate in the proliferation and cell death of human PBMC. *Arch Oral*
787 *Biol* 2012;57:314-320.
- 788 93. Yamazaki K, Ohsawa Y, Tabeta K, et al. Accumulation of human heat shock protein
789 60-reactive T cells in the gingival tissues of periodontitis patients. *Infect Immun*
790 2002;70:2492-2501.
- 791 94. Figueredo CM, Gustafsson A, Asman B, Bergström K. Expression of intracellular
792 elastase activity in peripheral neutrophils from patients with adult periodontitis. *J Clin*
793 *Periodontol* 2000;27:572-577.
- 794 95. Champagne CM, Vaikuntam J, Warbington ML, Rose L, Daniel MA, Van Dyke TE.
795 Cytoskeletal actin reorganization in neutrophils from patients with localized juvenile
796 periodontitis. *J Periodontol* 1998;69:209-218.
- 797 96. Kumar RS, Prakash S. Impaired neutrophil and monocyte chemotaxis in chronic and
798 aggressive periodontitis and effects of periodontal therapy. *Indian J Dent Res*
799 2012;23:69.
- 800 97. Roberts HM, Ling MR, Insall R, et al. Impaired neutrophil directional chemotactic
801 accuracy in chronic periodontitis patients. *J Clin Periodontol* 2015;42:1-11.

- 802 98. Srinivas M, Chethana KC, Padma R, et al. A study to assess and compare the
803 peripheral blood neutrophil chemotaxis in smokers and non smokers with healthy
804 periodontium, gingivitis, and chronic periodontitis. *J Indian Soc Periodontol*
805 2012;16:54-58.
- 806 99. Van Dyke TE, Levine MJ, Tabak LA, Genco RJ. Reduced chemotactic peptide
807 binding in juvenile periodontitis: a model for neutrophil function. *Biochem Biophys*
808 *Res Commun* 1981;100:1278-1284.
- 809 100. Van Dyke TE, Levine MJ, Tabak LA, Genco RJ. Juvenile periodontitis as a model for
810 neutrophil function: reduced binding of the complement chemotactic fragment, C5a. *J*
811 *Dent Res* 1983;62:870-872.
- 812 101. Zhang F, Yang XM, Jia SY. Characteristics of neutrophil extracellular traps in
813 patients with periodontitis and gingivitis. *Braz Oral Res* 2020;34:e015.
- 814 102. Asif K, Kothiwale SV. Phagocytic activity of peripheral blood and crevicular
815 phagocytes in health and periodontal disease. *J Indian Soc Periodontol* 2010;14:8-11.
- 816 103. Carneiro VM, Bezerra AC, Guimarães Mdo C, Muniz-Junqueira MI. Decreased
817 phagocytic function in neutrophils and monocytes from peripheral blood in
818 periodontal disease. *J Appl Oral Sci* 2012;20:503-509.
- 819 104. Gonzales JR, Gröger S, Boedeker RH, Meyle J. Expression and secretion levels of
820 Th1 and Th2 cytokines in patients with aggressive periodontitis. *Clin Oral Investig*
821 2012;16:1463-1473.
- 822 105. Berker E, Kantarci A, Hasturk H, Van Dyke TE. Blocking proinflammatory cytokine
823 release modulates peripheral blood mononuclear cell response to *Porphyromonas*
824 *gingivalis*. *J Periodontol* 2013;84:1337-1345.
- 825 106. Hurttia HM, Pelto LM, Leino L. Evidence of an association between functional
826 abnormalities and defective diacylglycerol kinase activity in peripheral blood

- 827 neutrophils from patients with localized juvenile periodontitis. *J Periodontal Res*
828 1997;32:401-407.
- 829 107. Fokkema S, Loos B, De Slegte C, et al. Increased release of IL-12p70 by monocytes
830 after periodontal therapy. *J Clin Periodontol* 2003;30:1091-1096.
- 831 108. Bajestan MN, Radvar M, Afshari JT, Naseh MR, Arab HR. Interleukin-6 production
832 by cultured peripheral blood monocytes before and after stimulation by *E. coli*
833 lipopolysaccharide in Iranian patients with aggressive periodontitis. *Med Sci Monit*
834 2006;12:393-396.
- 835 109. Gonzales JR, Groeger S, Johansson A, Meyle J. T helper cells from aggressive
836 periodontitis patients produce higher levels of interleukin-1 beta and interleukin-6 in
837 interaction with *Porphyromonas gingivalis*. *Clin Oral Investig* 2014;18:1835-1843.
- 838 110. Radvar M, Tavakkol-Afshari J, Bajestan MN, Naseh MR, Arab HR. The effect of
839 periodontal treatment on IL-6 production of peripheral blood monocytes in aggressive
840 periodontitis and chronic periodontitis patients. *Iran J Immunol* 2008;5:100-106.
- 841 111. Borilova Linhartova P, Danek Z, Deissova T, et al. Interleukin Gene Variability and
842 Periodontal Bacteria in Patients with Generalized Aggressive Form of Periodontitis.
843 *Int J Mol Sci* 2020;21.
- 844 112. Nogueira-Filho G, Rosa BT, Santos PF, et al. Whole-blood cultures from patients
845 with chronic periodontitis respond differently to *Porphyromonas gingivalis* but not
846 *Escherichia coli* lipopolysaccharide. *J Periodontol* 2014;85:e18-23.
- 847 113. Galbraith GM, Hagan C, Steed RB, Sanders JJ, Javed T. Cytokine production by oral
848 and peripheral blood neutrophils in adult periodontitis. *J Periodontol* 1997;68:832-
849 838.

- 850 114. Mahanonda R, Sa-Ard-Iam N, Charatkulangkun O, et al. Monocyte activation by
851 Porphyromonas gingivalis LPS in aggressive periodontitis with the use of whole-
852 blood cultures. *J Dent Res* 2004;83:540-545.
- 853 115. de Heens GL, van der Velden U, Loos BG. Cigarette smoking enhances T cell
854 activation and a Th2 immune response; an aspect of the pathophysiology in
855 periodontal disease. *Cytokine* 2009;47:157-161.
- 856 116. Restaino CG, Chaparro A, Valenzuela MA, et al. Stimulatory response of neutrophils
857 from periodontitis patients with periodontal pathogens. *Oral Dis* 2007;13:474-481.
- 858 117. Shapira L, Soskolne WA, Van Dyke TE. Prostaglandin E2 secretion, cell maturation,
859 and CD14 expression by monocyte-derived macrophages from localized juvenile
860 periodontitis patients. *J Periodontol* 1996;67:224-228.
- 861 118. Fokkema S, Loos B, Van Der Velden U. Monocyte-derived RANTES is intrinsically
862 elevated in periodontal disease while MCP-1 levels are related to inflammation and
863 are inversely correlated with IL-12 levels. *Clin Exp Immunol* 2003;131:477-483.
- 864 119. MacFarlane GD, Herzberg MC, Wolff LF, Hardie NA. Refractory periodontitis
865 associated with abnormal polymorphonuclear leukocyte phagocytosis and cigarette
866 smoking. *J Periodontol* 1992;63:908-913.
- 867 120. Brunetti G, Colucci S, Pignataro P, et al. T cells support osteoclastogenesis in an in
868 vitro model derived from human periodontitis patients. *J Periodontol* 2005;76:1675-
869 1680.
- 870 121. Medara N, Lenzo JC, Walsh KA, Reynolds EC, O'Brien-Simpson NM, Darby IB.
871 Peripheral neutrophil phenotypes during management of periodontitis. *J Periodontal*
872 *Res* 2021;56:58-68.

- 873 122. Górská R, Laskus-Perendyk A, Gregorek H, Kowalski J. The influence of surgical
874 treatment of periodontal disease on selected lymphocyte subpopulations important for
875 cellular and humoral immune responses. *J Periodontol* 2005;76:1304-1310.
- 876 123. Piconi S, Trabattoni D, Luraghi C, et al. Treatment of periodontal disease results in
877 improvements in endothelial dysfunction and reduction of the carotid intima-media
878 thickness. *FASEB J* 2009;23:1196-1204.
- 879 124. Rajendran M, Looney S, Singh N, et al. Systemic antibiotic therapy reduces
880 circulating inflammatory dendritic cells and Treg–Th17 plasticity in periodontitis. *J*
881 *Immunol* 2019;202:2690-2699.
- 882 125. Zhao L, Zhou Y, Xu Y, Sun Y, Li L, Chen W. Effect of non-surgical periodontal
883 therapy on the levels of Th17/Th1/Th2 cytokines and their transcription factors in
884 Chinese chronic periodontitis patients. *J Clin Periodontol* 2011;38:509-516.
- 885 126. Berglundh T, Liljenberg B, Lindhe J. Some effects of periodontal therapy on local and
886 systemic immunological parameters. *J Clin Periodontol* 1999;26:91-98.
- 887 127. Czesnikiewicz-Guzik M, Osmenda G, Siedlinski M, et al. Causal association between
888 periodontitis and hypertension: evidence from Mendelian randomization and a
889 randomized controlled trial of non-surgical periodontal therapy. *Eur Heart J*
890 2019;40:3459-3470.
- 891 128. Okada H. Phenotypic and functional characterization of peripheral blood T cells in
892 adult periodontitis. *J Periodontal Research* 1991;26:289-292.
- 893 129. Shin J, Kho S-A, Choi YS, Kim YC, Rhyu I-C, Choi Y. Antibody and T cell
894 responses to *Fusobacterium nucleatum* and *Treponema denticola* in health and chronic
895 periodontitis. *PLoS One* 2013;8:e53703.

- 896 130. Evans R, Mikulecky M, Seymour G. Effect of initial treatment of chronic
897 inflammatory periodontal disease in adults on spontaneous peripheral blood
898 lymphocyte proliferation. *J Clin Periodontol* 1989;16:271-277.
- 899 131. Carneiro V, Bezerra A, Guimarães M, Muniz-Junqueira MI. Effects of periodontal
900 therapy on phagocytic activity of peripheral blood neutrophils—evidence for an
901 extrinsic cellular defect. *Oral Health Prev Dent* 2012;10:195-203.
- 902 132. Budtz-Jørgensen E, Ellegaard B, Ellegaard J, Jørgensen F, Kelstrup J. The effect of
903 levamisole on experimental gingivitis in juvenile periodontitis: Sequential clinical,
904 immunological, and haematological changes. *J Periodontal Res* 1978;13:460-473.
- 905 133. White P, Sakellari D, Roberts H, et al. Peripheral blood neutrophil extracellular trap
906 production and degradation in chronic periodontitis. *J Clin Periodontol*
907 2016;43:1041-1049.
- 908 134. Papapanou PN, Sedaghatfar MH, Demmer RT, et al. Periodontal therapy alters gene
909 expression of peripheral blood monocytes. *J Clin Periodontol* 2007;34:736-747.
- 910 135. Higuchi K, Ziauddin S, Yamashita Y, Ozaki Y, Yoshimura A. Initial periodontal
911 treatment affects nucleotide-binding domain leucine-rich repeat-containing protein 3
912 inflammasome priming in peripheral blood mononuclear cells. *Arch Oral Biol*
913 2020;110:104625.
- 914 136. Ishikado A, Uesaki S, Suido H, et al. Human trial of liposomal lactoferrin
915 supplementation for periodontal disease. *Biol Pharm Bull* 2010;33:1758-1762.
- 916 137. Zhu H, Hu F, Sun X, et al. CD16+ monocyte subset was enriched and functionally
917 exacerbated in driving T-cell activation and B-cell response in systemic lupus
918 erythematosus. *Front Immunol* 2016;7:512.
- 919 138. Lacerte P, Brunet A, Egarnes B, Duchêne B, Brown JP, Gosselin J. Overexpression of
920 TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients

- 921 contributes to enhance responsiveness to TLR agonists. *Arthritis Res Ther* 2016;18:1-
922 14.
- 923 139. Chiu YG, Shao T, Feng C, et al. CD16 (FcR γ III) as a potential marker of osteoclast
924 precursors in psoriatic arthritis. *Arthritis Res Ther* 2010;12:1-14.
- 925 140. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte
926 homeostasis in systemic lupus erythematosus. *J Immunol* 2000;165:5970-5979.
- 927 141. Böhm I. Increased peripheral blood B-cells expressing the CD5 molecules in
928 association to autoantibodies in patients with lupus erythematosus and evidence to
929 selectively down-modulate them. *Biomed Pharmacother* 2004;58:338-343.
- 930 142. Szegedi A, Aleksza M, Gonda A, et al. Elevated rate of Thelper1 (TH1) lymphocytes
931 and serum IFN- γ levels in psoriatic patients. *Immunol Lett* 2003;86:277-280.
- 932 143. Guo R, Zhang T, Meng X, et al. Lymphocyte mass cytometry identifies a CD3-CD4+
933 cell subset with a potential role in psoriasis. *JCI Insight* 2019;4.
- 934 144. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased
935 secretion of pro-inflammatory cytokines by circulating polymorphonuclear
936 neutrophils and regulation by interleukin 10 during intestinal inflammation. *Gut*
937 1998;42:470-476.
- 938 145. Somasundaram R, Nuij VJ, van der Woude CJ, Kuipers EJ, Peppelenbosch MP,
939 Fuhler GM. Peripheral neutrophil functions and cell signalling in Crohns disease.
940 *PLoS One* 2013;8:e84521.
- 941 146. Gemmell E, Carter C, Grieco D, Sugerman P, Seymour G. P. gingivalis-specific T-
942 cell lines produce Th1 and Th2 cytokines. *J Dent Res* 2002;81:303-307.
- 943 147. Chavakis T, Mitroulis I, Hajishengallis G. Hematopoietic progenitor cells as
944 integrative hubs for adaptation to and fine-tuning of inflammation. *Nat Immunol*
945 2019;20:802-811.

- 946 148. Zhao Y, Li Z, Su L, et al. Frontline science: Characterization and regulation of
947 osteoclast precursors following chronic Porphyromonas gingivalis infection. *J Leukoc*
948 *Biol* 2020;108:1037-1050.
- 949 149. Konkel JE, O'Boyle C, Krishnan S. Distal consequences of oral inflammation. *Front*
950 *Immunol* 2019;10:1403.
- 951 150. Dias IH, Matthews JB, Chapple IL, Wright HJ, Dunston CR, Griffiths HR. Activation
952 of the neutrophil respiratory burst by plasma from periodontitis patients is mediated
953 by pro-inflammatory cytokines. *J Clin Periodontol* 2011;38:1-7.
- 954 151. Morgan MJ, Kim Y-S, Liu Z-g. TNF α and reactive oxygen species in necrotic cell
955 death. *Cell Res* 2008;18:343-349.
- 956 152. Blaser H, Dostert C, Mak TW, Brenner D. TNF and ROS Crosstalk in Inflammation.
957 *Trends Cell Biol* 2016;26:249-261.
- 958 153. Nagai Y, Garrett KP, Ohta S, et al. Toll-like receptors on hematopoietic progenitor
959 cells stimulate innate immune system replenishment. *Immunity* 2006;24:801-812.
- 960 154. Kitamoto S, Nagao-Kitamoto H, Jiao Y, et al. The intermucosal connection between
961 the mouth and gut in commensal pathobiont-driven colitis. *Cell* 2020;182:447-462.
962 e414.
- 963 155. Silva DS, Costa F, Baptista IP, et al. Evidence-based research on effectiveness of
964 periodontal treatment in rheumatoid arthritis patients: a systematic review and meta-
965 analysis. *Arthritis Care & Research* 2021.
- 966 156. Sun J, Zheng Y, Bian X, Ge H, Wang J, Zhang Z. Non-surgical periodontal treatment
967 improves rheumatoid arthritis disease activity: a meta-analysis. *Clinical Oral*
968 *Investigations* 2021:1-11.

- 969 157. Sete MRC, Carlos JC, Mello-Neto JM, et al. Impact of chronic gingivitis management
970 on the cytokine and anti-PPAD expressions in juvenile systemic lupus erythematosus:
971 A six-month follow-up. *Journal of Periodontal Research* 2021;56:1132-1140.
- 972 158. Ucan Yarkac F, Ogrum A, Gokturk O. Effects of non-surgical periodontal therapy on
973 inflammatory markers of psoriasis: A randomized controlled trial. *Journal of clinical*
974 *periodontology* 2020;47:193-201.
- 975 159. Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. *Nat Rev*
976 *Cardiol* 2020;17:387-401.
- 977 160. MacRitchie N, Grassia G, Noonan J, et al. The aorta can act as a site of naive CD4+
978 T-cell priming. *Cardiovasc Res* 2020;116:306-316.
- 979 161. Cuff CA, Kothapalli D, Azonobi I, et al. The adhesion receptor CD44 promotes
980 atherosclerosis by mediating inflammatory cell recruitment and vascular cell
981 activation. *J Clin Invest* 2001;108:1031-1040.
- 982 162. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease.
983 *Am J Hypertens* 2001;14:44S-54S.
- 984 163. Baragetti A, Garlaschelli K, Bonacina F, et al. Effector memory T cells predict
985 atherosclerosis progression and cardiovascular events over 4 years follow-up. *Nutr*
986 *Metab Cardiovasc Dis* 2017;27:e7.
- 987 164. Patel AA, Zhang Y, Fullerton JN, et al. The fate and lifespan of human monocyte
988 subsets in steady state and systemic inflammation. *J Exp Med* 2017;214:1913-1923.
- 989 165. Sander J, Schmidt SV, Cirovic B, et al. Cellular differentiation of human monocytes
990 is regulated by time-dependent interleukin-4 signaling and the transcriptional
991 regulator NCOR2. *Immunity* 2017;47:1051-1066. e1012.
- 992 166. Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen-
993 presenting functions. *Nat Rev Immunol* 2017;17:349-362.

- 994 167. Kapellos TS, Bonaguro L, Gemünd I, et al. Human monocyte subsets and phenotypes
995 in major chronic inflammatory diseases. *Front Immunol* 2019;10:2035.
- 996 168. Narasimhan PB, Marcovecchio P, Hamers AA, Hedrick CC. Nonclassical monocytes
997 in health and disease. *Ann Rev Immunol* 2019;37:439-456.
- 998 169. Higashi Y, Goto C, Jitsuiki D, et al. Periodontal infection is associated with
999 endothelial dysfunction in healthy subjects and hypertensive patients. *Hypertension*
1000 2008;51:446-453.
- 1001 170. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and
1002 inflammatory diseases. *Autoimmun Rev* 2014;13:668-677.
- 1003 171. Zeng C, Shi X, Zhang B, et al. The imbalance of Th17/Th1/Tregs in patients with
1004 type 2 diabetes: relationship with metabolic factors and complications. *J Mol Med*
1005 2012;90:175-186.
- 1006 172. Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a
1007 unique population of regulatory T cells that affect metabolic parameters. *Nat Med*
1008 2009;15:930-939.
- 1009 173. Qiao Y-c, Shen J, He L, et al. Changes of regulatory T cells and of proinflammatory
1010 and immunosuppressive cytokines in patients with type 2 diabetes mellitus: a
1011 systematic review and meta-analysis. *J Diabetes Res* 2016;2016.
- 1012 174. Winer DA, Winer S, Shen L, et al. B cells promote insulin resistance through
1013 modulation of T cells and production of pathogenic IgG antibodies. *Nat Med*
1014 2011;17:610-617.
- 1015 175. Shen L, Chng MHY, Alonso MN, Yuan R, Winer DA, Engleman EG. B-1a
1016 lymphocytes attenuate insulin resistance. *Diabetes* 2015;64:593-603.

- 1017 176. Harmon DB, Srikakulapu P, Kaplan JL, et al. Protective role for B-1b B cells and IgM
1018 in obesity-associated inflammation, glucose intolerance, and insulin resistance.
1019 *Arterioscler Thromb Vasc Biol* 2016;36:682-691.
- 1020 177. Misharin AV, Cuda CM, Saber R, et al. Nonclassical Ly6C⁻ monocytes drive the
1021 development of inflammatory arthritis in mice. *Cell Rep* 2014;9:591-604.
- 1022 178. Lawson CA, Brown AK, Bejarano V, et al. Early rheumatoid arthritis is associated
1023 with a deficit in the CD4⁺ CD25^{high} regulatory T cell population in peripheral
1024 blood. *Rheumatology* 2006;45:1210-1217.
- 1025 179. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid
1026 arthritis. *Nat Rev Rheumatol* 2009;5:549-553.
- 1027 180. Loetscher P, Ugucioni M, Bordoli L, et al. CCR5 is characteristic of Th1
1028 lymphocytes. *Nature* 1998;391:344-345.
- 1029 181. Meednu N, Zhang H, Owen T, et al. Production of RANKL by Memory B Cells: A
1030 Link Between B Cells and Bone Erosion in Rheumatoid Arthritis. *Arthritis Rheumatol*
1031 2016;68:805-816.
- 1032 182. Mantovani L, Wilder RL, Casali P. Human rheumatoid B-1a (CD5⁺ B) cells make
1033 somatically hypermutated high affinity IgM rheumatoid factors. *J Immunol*
1034 1993;151:473-488.
- 1035 183. Elkon K, Casali P. Nature and functions of autoantibodies. *Nat Clin Pract Rheumatol*
1036 2008;4:491-498.
- 1037 184. Malmström V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive
1038 rheumatoid arthritis: from triggering to targeting. *Nat Rev Immunol* 2017;17:60-75.
- 1039 185. Bugatti S, Manzo A, Montecucco C, Caporali R. The Clinical Value of
1040 Autoantibodies in Rheumatoid Arthritis. *Front Med* 2018;5:339.

1041 186. Grimes DA, Schulz KF. An overview of clinical research: the lay of the land. *Lancet*
1042 2002;359:57-61.